



**Thermosensitive hybrid hyaluronan/ p(HPMAM-lac)-PEG hydrogels enhance cartilage regeneration in a mouse model of osteoarthritis**

Journal:	<i>Journal of Cellular Physiology</i>
Manuscript ID	JCP-19-0365.R1
Wiley - Manuscript type:	Original Research Article
Date Submitted by the Author:	16-Mar-2019
Complete List of Authors:	<p>Agas, Dimitrios; Universita degli Studi di Camerino, School of Biosciences and Biotechnology          Laus, Fulvio; University of Camerino, School of Biosciences and Veterinary Medicine          Lacava, Giovanna; Universita degli Studi di Camerino, School of Biosciences and Biotechnology          Marchegiani, Andrea; University of Camerino, School of Biosciences and Veterinary Medicine          Deng, Siyuan; Universita degli Studi di Camerino          Magnoni, Federico; Universita degli Studi di Camerino          Gusmão Silva, Guilherme; Universidade Federal de Minas Gerais          DiMartino, Piera; University of Camerino, School of Pharmacy          Sabbieti, Maria Giovanna; Universita degli Studi di Camerino, School of Biosciences and Veterinary Medicine          Censi, Roberta; University of Camerino, Camerino, School of Pharmacy</p>
Key Words:	osteoarthritis, hyaluronic acid, thermosensitive hydrogels, controlled release

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 1 **Thermosensitive hybrid hyaluronan/ p(HPMAm-lac)-PEG hydrogels**  
5  
6 2 **enhance cartilage regeneration in a mouse model of osteoarthritis**  
7  
8  
9 3

10  
11 4 Dimitrios Agas<sup>1</sup>, Fulvio Laus<sup>2</sup>, Giovanna Lacava<sup>1</sup>, Andrea Marchegiani<sup>2</sup>, Siyuan  
12 5 Deng<sup>3</sup>, Federico Magnoni<sup>3</sup>, Guilherme Gusmão Silva<sup>1,4</sup>, Piera Di Martino<sup>3</sup>, Maria  
13 6 Giovanna Sabbieti<sup>1§</sup>, Roberta Censi<sup>3§</sup>  
14  
15  
16  
17 7

18 8 <sup>1</sup> School of Biosciences and Veterinary Medicine, University of Camerino Via Gentile  
19 9 III da Varano - 62032 Camerino (MC), Italy

20 10 <sup>2</sup> School of Biosciences and Veterinary Medicine, University of Camerino, Via  
21 11 Circonvallazione 93/95 - 62024 Matelica (MC), Italy

22 12 <sup>3</sup> School of Pharmacy, University of Camerino, Via. S. Agostino, 1 - 62032 Camerino  
23 13 (MC), Italy

24 14 <sup>4</sup> Departamento de Bioquímica e Imunologia, Universidade Federal de Minas Gerais,  
25 15 Belo Horizonte, Minas Gerais, Brazil  
26  
27  
28  
29  
30  
31  
32  
33

34 17 § The authors equally contributed to this work  
35  
36  
37

38 19 **Corresponding authors:** Dimitrios Agas, School of Biosciences and Veterinary  
39 20 Medicine, University of Camerino, Via Gentile III da Varano, I-62032 Camerino  
40 21 (MC) Italy; Tel. +39-737-402713/15; e-mail: [dimitrios.agas@unicam.it](mailto:dimitrios.agas@unicam.it)

41 22 Maria Giovanna Sabbieti, School of Biosciences and Veterinary Medicine,  
42 23 University of Camerino, Via Gentile III da Varano, I-62032 Camerino (MC) Italy;  
43 24 Tel. +39-737-402715; e-mail: [giovanna.sabbieti@unicam.it](mailto:giovanna.sabbieti@unicam.it)  
44  
45  
46  
47  
48  
49  
50

51 26 **Author contribution statement**

52 27 G.L., S.D., F.M. performed the experiments, R.C., D.A, M.G.S., P.D.M. designed the  
53 28 experiments, analysed the data, and wrote the manuscript, G.G.S., A.M. performed the  
54 29 statistical analysis, F.L., A.M. performed and supervised the animal treatments, P.D.M.  
55 30 and M.G.S. provided the financial support to the study.  
56  
57  
58  
59  
60

1  
2  
3  
4 31 **Running Head:** Hybrid hyaluronan/p(HPMAm-lac)-PEG hydrogels in cartilage  
5 32 regeneration

6 33 **Keywords:** osteoarthritis, hyaluronic acid, thermosensitive hydrogels, controlled  
7 34 release, degradation.

8  
9 35 **Total number of figures:** 6

10 36 **Funding statement:** This project was supported by the EU research grant H2020-  
11 37 MSCA-ITN- 2015 number 675743, by the EU research grant H2020-MSCA-RISE-  
12 38 2016 number 734684, by an H2020-MSCA-RISE-2017 award through the CANCER  
13 39 project (grant number 777682) and by FAR Unicam research grant number BVI000014.

14 40 **Conflict of interest statement**

15 41 The authors declare that the research was conducted in the absence of any commercial  
16 42 or financial relationships that could be construed as a potential conflict of interest

17 43

18 44 **ABSTRACT**

19 45

20 46 Osteoarthritis, due to cartilage degeneration, is one of the leading causes of  
21 47 disability worldwide. Currently, there are not efficacious therapies to reverse cartilage  
22 48 degeneration. In this study we evaluated the potential of hybrid hydrogels, composed  
23 49 of a biodegradable and thermosensitive triblock copolymer cross-linked via Michael  
24 50 addition to thiolated hyaluronic acid, in contrasting inflammatory processes underlying  
25 51 osteoarthritis. Hydrogels composed of different w/w % concentrations of hyaluronan  
26 52 were investigated for their degradation behavior and capacity to release the  
27 53 polysaccharide in a sustained fashion. It was found that hyaluronic acid was  
28 54 controllably released during network degradation with a zero-order release kinetics, and  
29 55 the release rate depended on cross-link density and degradation kinetics of the  
30 56 hydrogels. When locally administered in vivo in an osteoarthritis mouse model, the  
31 57 hydrogels demonstrated ability to restore, to some extent, bone remineralization,  
32 58 proteoglycan production, levels of Sox-9 and Runx-2. Furthermore, the downregulation  
33 60

1  
2  
3 59 of pro-inflammatory mediators, such as TNF- $\alpha$ , NF $\kappa$ B, and RANKL and pro-  
4  
5 60 inflammatory cytokines was observed. In summary, the investigated hydrogel  
6  
7 61 technology represents an ideal candidate for the potential encapsulation and release of  
8  
9 62 drugs relevant in the field of osteoarthritis. In this context, the hydrogel matrix could  
10  
11 63 act in synergy with the drug, in reversing phenomena of inflammation, cartilage  
12  
13 64 disruption and bone demineralization associated with osteoarthritis.  
14  
15  
16  
17  
18

65

## 66 INTRODUCTION

67

68 Osteoarthritis (OA) is a progressive, degenerative joint disease that affects, only in  
69 the US, over 30 million people over 50 years of age, involving not only the elderly, but  
70 also young and active individuals with prolonged participation in physical-demanding  
71 activities (Zhang and Jordan, 2010). OA is characterized by the damage or breakdown  
72 of articular cartilage and subchondral bone, particularly those of the hands, hips and  
73 knees. The transient proliferative response of chondrocytes observed in early OA is  
74 progressively suppressed by the increased synthesis of catabolic cytokines and matrix-  
75 degrading enzymes in the chronic stage of the disease (Goldring, 2000). The degrading  
76 cartilage matrix shows increased water content and lower tensile strength, leading to  
77 symptomatic pain, joint stiffness, swelling, and disability for the patients (Sophia Fox  
78 et al., 2009). Cytological and histological aberrations, typical of inflammatory  
79 synovitis, such as synovial lining hyperplasia, infiltration of macrophages and  
80 lymphocytes, neoangiogenesis and fibrosis are often associated with OA (Scanzello and  
81 Goldring, 2012). From a biochemical point of view, engagement of Toll-like receptors,  
82 activation of the complement cascade, and the synthesis and release of a wide variety

1  
2  
3 83 of cytokines and chemokines are the expression of the inflammatory processes  
4  
5 84 underlying OA (Scanzello and Goldring, 2012; Sellam and Berenbaum, 2010).  
6  
7  
8 85 Currently, treatments to halt OA disease progression are not available. Symptomatic  
9  
10 86 treatment of the affection is the only practicable option, with the use of analgesics, non-  
11  
12 87 steroidal anti-inflammatory drugs, corticosteroids being the most commonly applied  
13  
14 88 therapies. However, these pharmacological approaches did not prove long-term  
15  
16 89 efficacy and and they have all been associated with adverse effects (Bellamy et al.,  
17  
18 90 2006; Raynauld et al., 2003). At the end stage of the disease, arthroplasty is usually  
19  
20 91 needed (McAlindon et al., 2014). Recently, new strategies, such as anti-cytokine  
21  
22 92 therapy, gene therapy, delivery of growth factors, stem-cell therapy, and new lubricant  
23  
24 93 agents, such as lubricin, have been proposed (Chevalier et al., 2010).  
25  
26 94 Viscosupplementation of hyaluronic acid (HA) is used to augment the viscoelastic  
27  
28 95 properties of OA synovial fluid, which has been shown to have a lower concentration  
29  
30 96 and molecular weight of HA compared to healthy fluid (Moreland, 2003). The  
31  
32 97 hyaluronan in normal synovial fluid plays an important role in joint homeostasis. It  
33  
34 98 contributes to joint lubrication, buffers load transmission across articular surfaces,  
35  
36 99 provides a renewed source of hyaluronan to joint tissues, and imparts anti-nociceptive  
37  
38 100 and anti-inflammatory properties to synovial fluid (Marshall, 2000). There are currently  
39  
40 101 several commercially available hyaluronate or hyaluronate derived  
41  
42 102 viscosupplementation agents composed of native sodium hyaluronate (e.i. Hyalgan®,  
43  
44 103 Sanofi-Synthelabo Inc., New York, NY), or chemically cross-linked hyaluronic acid  
45  
46 104 (e.i. Hylan G-F 20, Synvisc®, Wyeth-Ayerst, Philadelphia, PA). The residence time of  
47  
48 105 HA upon intraarticular injection is relatively short for the non-crosslinked polymer (24  
49  
50 106 hours), while the chemically cross-linked HA resided in the synovium for over 28 days.  
51  
52  
53  
54  
55  
56  
57  
58 107 However, the degradation kinetics of such polysaccharides are poorly controllable, as  
59  
60

1  
2  
3 108 mainly mediated by phagocytosis (Jackson and Simon, 2006). The scope of the present  
4  
5 109 work was to investigate the anti-inflammatory effect in an osteoarthritic mouse model  
6  
7 110 of low molecular weight HA, that was chemically cross-linked to and controllably  
8  
9 111 release from a new hydrogel system, via a mechanism mediated by hydrolysis rather  
10  
11 112 than cellular metabolism. Hydrogels are water swollen three-dimensional polymer  
12  
13 113 networks that hold potential in the field of cartilage regeneration, as they can act both  
14  
15 114 as scaffolding materials and/or releasing matrices for biologically active and cell  
16  
17 115 modulating substances. Their water content, soft nature and porous structure mimic  
18  
19 116 biological tissues and make them suitable to accommodate cells and to encapsulate and  
20  
21 117 release water-soluble compounds like proteins in a controlled fashion (Censi et al.,  
22  
23 118 2012).

24  
25  
26  
27  
28 119 The hydrogel used in the present work was previously designed (Dubbini et al., 2015)  
29  
30 120 and appropriately optimized in the present work for the application in osteoarthritis  
31  
32 121 management. The administration strategy is minimally invasive, as the system is  
33  
34 122 thermos-responsive, therefore undergoes phase transition at body temperature,  
35  
36 123 generating a hydrogel depot at the site of injection. Furthermore, the system is fully  
37  
38 124 degradable via a mechanism that mainly depends on polymer hydrolysis (Censi et al.,  
39  
40 125 2010).

41  
42  
43  
44 126 In our previous studies, we showed the design and synthesis of a new hyaluronic  
45  
46 127 acid/PEG-p(HPMAm-lac)-based hydrogel and demonstrated its potential as cell and  
47  
48 128 protein carrier. Also, we tested its biocompatibility in vitro and in vivo (Sabbieti et al.,  
49  
50 129 2017). In the present study, we investigated its efficacy in osteoarthritic mouse models  
51  
52 130 in reducing articular inflammation by the controlled delivery of HA. This study will  
53  
54 131 pave the way towards the application of the HA-cross-linked hydrogel as delivery  
55  
56 132 system for regenerative molecules for cartilage tissue engineering, such as anti RANKL  
57  
58  
59  
60

1  
2  
3 133 antibodies. The local administration of such drugs may potentially minimize side  
4  
5 134 effects compared to intravenous administration, that usually requires large doses  
6  
7  
8 135 because of its poor localization to diseased joints.  
9

10 136  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review

137


138 **MATERIAL AND METHODS**139 **Materials**

140 Unless indicated otherwise, all the chemicals were obtained from Sigma-Aldrich and  
 141 used as received. Sodium hyaluronate with a molecular weight of 37900 Da was  
 142 supplied by LIFECORE BIOMEDICAL. Hydroxypropyl methacrylamide mono- and  
 143 di-lactate (HPMAM-lac<sub>1</sub> and HPMAM-lac<sub>2</sub>) were synthesized according to a previously  
 144 reported method (Soga et al., 2004). The synthesis of triblock copolymers with PEG as  
 145 middle block and poly(HPMAM-lac<sub>1-2</sub>) as outer blocks was described previously  
 146 (Vermonden et al., 2006). 3,3'-Dithiobis(propanoic dihydrazide) (DTP) was  
 147 synthesized by the method described by Vercruyssen et al., 1997.

148

149 **Methods**


150



151

152 **Scheme 1.** One-Pot Synthesis procedure for vinyl sulfonated triblock copolymers based  
 153 on poly(HPMAM-lac<sub>1-2</sub>)-PEG- poly(HPMAM-lac<sub>1-2</sub>)





**Scheme 2.** Synthesis route of thiolated hyaluronic acid

### *Synthesis of Vinyl Sulfonated triblock copolymer*

Triblock copolymers of an aimed degree of substitution (DS) of 0, 10 and 15% were synthesized and indicated as VinylSulTC\_0, VinylSulTC\_10 and VinylSulTC\_15, respectively. The DS is defined as the number of vinyl sulfone groups per lactate residues. As an example, the synthesis procedure of VinylSulTC\_10 is reported. Divinyl sulfone (DVS) (0.114 mol) was dissolved in 100 ml dimethyl sulfoxide (DMSO). Subsequently, 3-Mercapto propionic acid (3-MPA) (0.0057 mol), was added dropwise at a molar ratio of 1:20 compared to DVS and the reaction was stirred at room temperature for 4 h. Separately, p(HPMAM-lac)-PEG (0.000221 mol), 4-(Dimethylamino)pyridinium 4-toluensulfonate (DPTS) (0.00085 mol, molar ratio of DPTS to 3-MPA of 0.15:1), N,N'-Dicyclohexylcarbodiimide (DCC) (0.0085 mol, molar ratio of DCC to 3-MPA is 1.5:1) were dissolved in DMSO (10 ml per gram of triblock copolymer) and added dropwise to the previous mixture at a molar ratio between free hydroxyl groups of p(HPMAM-lac)-PEG and 3-MPA of 1:0.20 and

1  
2  
3 171 reacted for 24 h at room temperature. The vinyl sulfone modified triblock copolymer  
4  
5 172 p(HPMAm-lac)-PEG was purified by dialysis for 48 h at 4°C against water (MWCO  
6  
7 173 12-14 KDa) and freeze-dried (Hiemstra et al., 2007; Dubbini et al., 2015). The  
8  
9 174 synthesized product was characterized by <sup>1</sup>H-NMR, GPC and light scattering. The DS  
10  
11 175 was determined by <sup>1</sup>H-NMR and calculated from the ratio of the intensity of the peaks  
12  
13 176 at 6.3-6.2 and 6.9 and intensity of the peak at 5.4-5.2 ppm according to the equation:

14  
15  
16  
17 177 
$$(I_{6.3-6.2} + I_{6.9} / 3) / (I_{6.3-6.2} + I_{6.9} / 3 + I_{5.4-5.2}) \times 100.$$

18  
19 178 *Before Vinyl sulfonation.* <sup>1</sup>H-NMR, CDCl<sub>3</sub>, δ in ppm: 6.9 (1H, -NHCH<sub>2</sub>CHCH<sub>3</sub>), 5.0  
20  
21 179 (2H, -NHCH<sub>2</sub>CH(CH<sub>3</sub>)O and -COCH(CH<sub>3</sub>)O), 4.4 (1H, -COCH(CH<sub>3</sub>)OH), 3.8-3.4  
22  
23 180 (909 H, -OCH<sub>2</sub>CH<sub>2</sub> PEG protons), 3.1 (2H, -NHCH<sub>2</sub>), 2.2-0.8 (main chain protons).

24  
25  
26 181 *After Vinyl sulfonation.* <sup>1</sup>H-NMR, DMSO-d<sub>6</sub>, δ in ppm: 7.3 (1H, -NHCH<sub>2</sub>CHCH<sub>3</sub>), 6.9  
27  
28 182 (1H, -SO<sub>2</sub>CH=CH<sub>2</sub>), 6.3-6.2 (2H, -SO<sub>2</sub>CH=CH<sub>2</sub>), 5.4-5.2 (1H, -OHCHCH<sub>3</sub>), 4.9-4.8  
29  
30 183 (2H, -NHCH<sub>2</sub>CH(CH<sub>3</sub>)O and -COCH(CH<sub>3</sub>)O), 4.2-4.1 (1H, -COCH(CH<sub>3</sub>)OH), 3.5  
31  
32 184 (909 H, -OCH<sub>2</sub>CH<sub>2</sub> PEG protons), 2.7 (8H, -CH<sub>2</sub>CH<sub>2</sub>SCH<sub>2</sub>CH<sub>2</sub>) 1.7-0.7 (main chain  
33  
34 185 protons).

35  
36  
37  
38  
39  
40 187 ***Synthesis of Thiolated Hyaluronic Acid (HA-SH)***

41  
42 188 Thiolated hyaluronic acid was synthesized slightly modifying the procedure described  
43  
44 189 by Shu et al., (2002). One gram of sodium hyaluronate (Mn 37.9kDa) was dissolved in  
45  
46 190 100 ml of sterile water and 482 mg of 3-3'-dithiobis propanoic diidrazide (DTP) was  
47  
48 191 added while stirring. The pH was adjusted to 4.75 with HCl 2 M and, subsequently, 388  
49  
50 192 mg of 1-ethyl-3-[3-(dimethylamino)propyl]-carbodiimide (EDC) was added while  
51  
52 193 keeping the pH at 4.75. The solution was stirred at room temperature for 48 h and the  
53  
54 194 reaction was stopped by increasing the pH to pH 7 with NaOH 5 M. Then, 1.5 g of  
55  
56 195 Tris(2-carboxyethyl)phosphine hydrochloride (TCEP) was added as reducing agent.  
57  
58  
59  
60

1  
2  
3 196 The reaction mixture was stirred for additional 24 h. The mixture was purified by  
4  
5 197 dialysis (MWCO 12-14 kDa) against dilute HCl (pH 3.5) containing 100mM NaCl and  
6  
7 198 finally against water at 4 °C. The final product was obtained as a white powder after  
8  
9  
10 199 lyophilization (Censi et al., 2010). The degree of substitution (DS), defined as the  
11  
12 200 number of DTP residues per 100 disaccharide units, was determined by <sup>1</sup>H-NMR and  
13  
14 201 Ellman's method (Riener et al., 2012). The products obtained is indicated as HA-  
15  
16 202 SH\_56.  
17  
18 203 <sup>1</sup>H- NMR, D<sub>2</sub>O, δ in ppm: 4.6-3.2 protons of hyaluronic acid, 2.7 (CH<sub>2</sub>SH), 2.5  
19  
20 204 (CH<sub>2</sub>CH<sub>2</sub>SH), 1.8 (NHCOCH<sub>3</sub>).  
21  
22  
23  
24  
25

### 206 ***<sup>1</sup>H-NMR Spectroscopy***

207 NMR spectra were recorded with a Varian Mercury Plus 400 NMR spectrometer. The  
208 polymers were dissolved in CDCl<sub>3</sub>, DMSO-d<sub>6</sub> and D<sub>2</sub>O. Chemical shifts were referred  
209 to the solvent peak.  
210

### 211 ***Gel Permeation Chromatography (GPC)***

212 The weight average molecular weight (M<sub>w</sub>), the number average molecular weight  
213 (M<sub>n</sub>) and the Polydispersity Index (PDI) of the vinyl sulfonated triblock copolymer  
214 were determined by gel permeation chromatography (GPC) using a TSKgel  
215 G4000HHR column (TOSOH BIOSCIENCE), 7.8 mm ID x 30.0 cm L, pore size 5 μm.  
216 PEGs of defined molecular weights, ranging from 106 to 1015000 Da) were used as  
217 calibration standards. The eluent was THF, the elution rate was 1.0 ml/min and the  
218 temperature of the column was 35°C. The samples were dissolved in THF at a  
219 concentration of 5 mg/ml.  
220

1  
2  
3 221 ***Cloud point (CP)***  
4

5 222 The cloud point of the polymer was determined using a Zetasizer Nano-S90 of Malvern  
6  
7 223 Instruments. The temperature gradient range between 5°C to 40°C, 1°C/min. The  
8  
9 224 samples are dissolved in Ammonium Acetate buffer 120 mM pH 5.0 with the  
10  
11 225 concentration of 3-5 mg/ml.  
12  
13

14 226

15  
16  
17 227 ***Hydrogel formulation***  
18

19 228 For in vitro testing, hydrogels of a volume of 100 µL were prepared in cylindrically  
20  
21 229 shaped glass vials (diameter of 5 mm) as follows. VinylSulfTC\_10 or VinylSulfTC\_15  
22  
23 230 were dissolved in phosphate buffer at pH 7.4 for at least 2 hours at 4 °C. HA-SH\_56  
24  
25 231 was separately dissolved in phosphate buffer pH 7.4 at room temperature and gently  
26  
27 232 mixed to the previously prepared triblock copolymer solutions. Upon mixing, the  
28  
29 233 hydrogels were incubated at 37°C for 1 hour to allow thermal gelation and subsequent  
30  
31 234 Michael addition cross-linking. The final concentration of VinylSulfTC\_10 or  
32  
33 235 VinylSulfTC\_15 was 15% w/w, while the HA-SH\_56 solid content was calculated in  
34  
35 236 order to have a vinyl sulfones/thiol groups molar ratio of 1/1, resulting in 4.1 and 8.2%  
36  
37 237 w/w for VinylSulfTC\_10 and VinylSulfTC\_15 based hydrogels, respectively.  
38  
39

40  
41 238 Hydrogels used for *in vivo* studies were formulated using the same procedure described  
42  
43 239 above but sterile saline was used as solvent. The two polymer solutions were mixed  
44  
45 240 immediately upon injection and tandem thermal and chemical cross-linking occurred *in*  
46  
47 241 *vivo*, at the inoculation site. As a control, physical hydrogels composed of  
48  
49 242 VinylSulfTC\_0 dissolved in sterile saline at 15% w/w concentration were applied *in*  
50  
51 243 *vivo*.  
52  
53

54 244

55  
56  
57 245 ***Rheology***  
58  
59  
60

1  
2  
3 246 Rheological characterization was performed on a Physica – MCR 101 (Anton Paar)  
4  
5 247 rheometer equipped with a Peltier plate and a 20 mm 1° steel cone-plate geometry. A  
6  
7 248 layer of silicone oil of viscosity of 0.05 Pa.s was wrapped around the edge of the conical  
8  
9 249 geometry to prevent water evaporation. A temperature sweep test from 18 to 37°C at a  
10  
11 250 heating rate of 1°C/min was performed at a frequency of 1Hz and 1% strain were used.  
12  
13  
14

15 251

### 16 17 252 *Swelling and degradation test*

18  
19 253 Hydrogels, prepared as described in the previous section, were supplemented with 900  
20  
21 254 µL of saline phosphate buffered (PBS pH 7.4, 150 mM) and allowed to swell. The  
22  
23 255 swollen hydrogels were weighted at regular time intervals after removing the exceeding  
24  
25 256 buffer. Subsequently the buffer was refreshed. The swelling ratio of the hydrogels was  
26  
27 257 calculated from the initial hydrogel weight after preparation ( $W_0$ ) and the swollen  
28  
29 258 hydrogel weight after exposure to buffer ( $W_t$ ):

30  
31  
32  
33 259 Swelling Ratio (SR) =  $W_t / W_0$   
34

35 260

### 36 37 261 *HA release studies*

38  
39 262 Gels were prepared as described above and surmounted with 0.9 mL of PBS buffer pH  
40  
41 263 7.4. The vials were incubated at 37°C under gentle horizontal shaking. Next, 0.15 mL  
42  
43 264 of solution was withdrawn at regular intervals and replaced by an equal amount of fresh  
44  
45 265 buffer. The release of HA from the formulated hydrogels was determined by using an  
46  
47 266 Aure A base glycosaminoglycan colorimetric assay. Ten µl aliquots of the release  
48  
49 267 media were combined with 190 µl of 0.025 mg/ml Azure A in a 96-well plate. The  
50  
51 268 absorbance at 620 nm was measured on an Infinite 200 PRO, Tecan Spectrophotometer.  
52  
53 269 The concentration of HA in the solution was determined from an experimentally-  
54  
55 270 obtained calibration curve.  
56  
57  
58  
59  
60

271

272 ***Animal studies***

273 All the protocol and procedures employed (experimental animals and housing and  
274 husbandry) were ethically reviewed and approved by the Italian Ministry of Health,  
275 authorization n° 933/2016-PR, conforming to the Directive 2010/63/EU.

276

277 ***Animals and Treatments***

278 Balb/c male mice (Harlan SrL, San Pietro al Natisone Udine, Italy) weighing  
279 between 25 - 30 g were selected. Mice were kept in laminar-flow cage in standardized  
280 environmental conditions. Food and water were supplied ad libitum.

281 Mice (7-9 weeks old) were randomized in three groups (G1: control group; G2:  
282 experimental groups) and they were anesthetized by administration of 4% isoflurane  
283 (induction) followed by 2% isoflurane (maintenance) in combination with a 2:1 mixture  
284 of O<sub>2</sub>/N<sub>2</sub>O. Then, mice were intra-articularly injected in the left knee with only in  
285 sterile physiological saline (G1, *n*: 6) or with collagenase from *Clostridium*  
286 *histolyticum* (10 µg) using a 26-gauge (26 G) needle (G2, *n*: 30) (van der Kraan et al.,  
287 1990).

288 One week following collagenase administration, the two groups of mice were  
289 anesthetized with isoflurane-air mixture to perform X-ray analysis (as better described  
290 below) to confirm that the treatment with collagenase was able to induce osteoarthritis.  
291 Then, the G2 group was further divided in five subgroups and, after receiving  
292 anesthesia, they were intradermal injected close to hind limb knee joint as below  
293 detailed: G2b (*n* = 6) was administered with 50 µl of only physiological saline; G2c (*n*  
294 = 6) was administered with 50 µl control physically crosslinked hydrogel composed of  
295 15% w/w VinylSulfTC\_0 in saline and in the absence of hyaluronic acid (no HA); G2d,

1  
2  
3 296 ( $n = 6$ ) was administered with 50  $\mu$ l chemically crosslinked hydrogel composed of 15%  
4  
5 297 w/w VinylSulfTC\_10 at a DS of 8% and 4.1% w/w thiolated hyaluronic acid at a DS  
6  
7 298 of 56% in saline (HA 1x). G2e ( $n = 6$ ) was administered with 50  $\mu$ l chemically  
8  
9 299 crosslinked hydrogel composed of 15% w/w VinylSulfTC\_15 at a DS of 16% and 8.2%  
10  
11 300 w/w thiolated hyaluronic acid at a DS of 56% in saline (HA2x).

12  
13  
14 301 The group G2a did not received any further treatment. Also, since the effects of  
15  
16 302 the VinylSulfTC\_10/HA-SH\_56 hydrogel on healthy mice were previously reported  
17  
18 303 (Sabbieti et al., 2017), the G1 control group did not receive any further treatment; by  
19  
20 304 this way we avoid the unnecessary use of animals. Table 2 gives an overview of the  
21  
22 305 experimental plan for *in vivo* studies.

23  
24  
25 306 Three weeks after the treatments, anesthetized mice were subjected to X-ray  
26  
27 307 analysis (as better described below) and, immediately prior to be sacrificed, the  
28  
29 308 anesthetized mice underwent blood samples collection, by cardiac puncture, to measure  
30  
31 309 the level of seric cytokines. Then, all animals were sacrificed by CO<sub>2</sub> narcosis under  
32  
33 310 the supervision of authorized investigators. Anesthesia, X-ray and euthanasia were  
34  
35 311 performed by accredited veterinarian physician involved in these studies.

36  
37  
38  
39  
40 312

### 41 42 313 ***ROI and quantitative X-ray analysis***

43  
44 314 Anesthetized mice were positioned in dorsal recumbence, as previously described  
45  
46 315 (Agas et al., 2017), making sure that pelvis, femurs and tibias were included in  
47  
48 316 radiographs. A portable X-ray generator (Gierth HF 80/15 plus ULTRA LEICH, Gierth  
49  
50 317 X-Ray International GmbH, Germany) mounted on a stative with focal distance of 60  
51  
52 318 cm was used; X-ray applied dose was 54Kv for a time of 0,04 sec. Radiographs were  
53  
54 319 acquired in DICOM format with Fujifilm FCR Capsule X (Fujifilm Corporation, Japan)  
55  
56 320 and processed both with Osirix (Pixmeo SARL, Switzerland) and ImageJ

1  
2  
3 321 (<http://rsb.info.nih.gov/ij/>) software, according to image analysis protocols previously  
4  
5 322 reported (McManus and Grill, 2011; Waung et al., 2014). Bone mineral density (BMD)  
6  
7 323 was evaluated on the knee joint by OsiriX software. The areas selected were defined as  
8  
9  
10 324 the region of interest (ROI).

11  
12 325 Subsequently, the DICOM images were converted with ImageJ into TIFF images  
13  
14 326 and a 16 intervals pseudo-color scale was applied to the color scale. This scale starts  
15  
16 327 from black pixels (value of zero) and increased gradations of mineralization density are  
17  
18 328 represented in 16 equal intervals by a pseudo-color scheme to white pixels (value of  
19  
20 329 255). Hence, distribution of pixels in the same ROI, defined as above described, was  
21  
22 330 calculated and displayed as an histogram.

### 23 24 25 26 331 ***Histological analysis***

27  
28 332 Hind-limbs were dissected at the hip and fixed in 4% paraformaldehyde (PFA)  
29  
30 333 diluted in PBS for 72 h at 4°C 4%. Then, bones were decalcified in 14%  
31  
32 334 ethylenediaminetetraacetic acid (EDTA) solution (pH 7.1) at RT for 3 days under  
33  
34 335 constant agitation. Samples, after dehydration, were embedded with paraffin. Tissue  
35  
36 336 sections, 10-12 µm thick, were obtained by a microtome (Leica Reichert-Jung 2040).  
37  
38 337 Sections were stained with Safranin-O/fast green and graded for cartilage defect healing  
39  
40 338 using a cartilage scoring previously described (Glasson et al., 2007). Briefly, each knee  
41  
42 339 yielded 13e16 slides for scoring by two blinded observers using a modified semi-  
43  
44 340 quantitative grading scale 8, where 0 represented normal cartilage; 0.5: loss of Safranin-  
45  
46 341 O with no structural lesions; 1: roughened articular surface and small fibrillations; 2:  
47  
48 342 fibrillation below the superficial layer and some loss of lamina; 3: fibrillations  
49  
50 343 extending to the calcified cartilage across less than 20% of the cartilage width; 5:  
51  
52 344 fibrillation and erosions extending from 20 to 80% of the cartilage width; 6: cartilage  
53  
54 345 erosion extending beyond 80% of the cartilage width. Blinded histological scoring was  
55  
56  
57  
58  
59  
60



1  
2  
3 346 performed on the four quadrants: medial and lateral femoral condyles and medial and  
4  
5 347 lateral tibial plateaus.  
6  
7

8 348

9  
10 349 ***Total bone marrow cell (BMCs) and bone marrow stromal cell (BMSCs) preparation***  
11  
12 350 ***and cultures***  
13  
14

15 351 Long bones (femurs, tibiae and humeri) from the above mice groups (not used for  
16  
17 352 the histological analysis) were dissected free of adhering tissues. Epiphyses were  
18  
19 353 removed and the marrow cavity was flushed. Total Bone Marrow Cells (BMCs) were  
20  
21 354 cultured for 2 days in DMEM plus 10% heat-inactivated-fetal calf serum (HIFCS),  
22  
23 355 penicillin, and streptomycin (Invitrogen, Milano, Italy). Then, culture medium and cells  
24  
25 356 were collected to study the release of cytokines and chemokines and the pro-  
26  
27 357 inflammatory in the cells lysate, respectively.  
28  
29

30  
31 358 Other BMCs cells from the same mice groups were maintained in culture for 10  
32  
33 359 days in order to generate monolayers of adherent cells (Bianco et al., 2013), referred as  
34  
35 360 Bone Marrow Stromal Cells (BMSCs).  
36  
37

38 361

39  
40  
41 362 ***Cytokines and chemokines assay***  
42

43 363 The cytokine/chemokine profiles in supernatants of 2 days cultured BMCs  
44  
45 364 population as well as in serum samples were assessed by using Mouse Cytokine Array  
46  
47 365 Panel A kit (R&D Systems, Milano, Italy) accordingly to the manufacturer's  
48  
49 366 instructions. Immunoreactive dots were visualized using LiteAblot Turbo luminol  
50  
51 367 reagents (Euroclone, Milano, Italy) and Hyperfilm-ECL film (Euroclone, Milano, Italy)  
52  
53 368 and quantitated densitometrically.  
54  
55

56  
57 369  
58  
59  
60

**370 Western blotting**

371 Proteins from total BMCs and from BMSCs were extracted in Cell Lysis Buffer  
372 (Cell Signaling Euroclone, Milano, Italy) after 2 days of cultures and the concentration  
373 was determined by the BCA protein assay reagent (Pierce, Euroclone Milano, Italy).  
374 Western blotting was performed as previously described (Sabbieti et al., 2010).  
375 Membranes were immunoblotted in blocking buffer with specific antibodies: rabbit  
376 anti-TNF $\alpha$  and rabbit anti-NF-kB (BioLegend, Microtech SrL, Napoli, Italy) both  
377 diluted 1:500; mouse anti-RANKL and rabbit anti-Runx-2 (Abcam, Prodotti Gianni,  
378 Milano, Italy) all diluted 1:600; rabbit anti-SOX-2 (Santa Cruz Biotechnology, Inc.  
379 DBA, Milano, Italy) diluted 1:300. After washing with PBS-T, blots were incubated  
380 with horseradish peroxidase (HRP)-conjugated donkey anti-rabbit IgG (Cell Signaling,  
381 Euroclone Milano, Italy) both diluted 1:50,000. Immunoreactive bands were visualized  
382 using LiteAblot Turbo luminol reagents (Euroclone, Milano, Italy) and Hyperfilm-ECL  
383 film (Euroclone, Milano, Italy) accordingly to the manufacturer's instructions. To  
384 normalize the bands, filters were stripped and re probed with a monoclonal anti- $\alpha$ -  
385 tubulin (Sigma-Aldrich, Milano, Italy). Bands density was quantified  
386 densitometrically.

**388 Statistical analysis**

389 All data were expressed as a mean  $\pm$  standard error (S.E.). Two-way analysis of  
390 variance (ANOVA) was used to compare the among the mice groups. Tukey test was  
391 used in multiple comparisons among all groups. All the statistical analyses were  
392 performed using the GraphPad Prism (v 6.01) on a personal computer O.S. Windows  
393 10. Data were presented as mean  $\pm$  S.E. Values of  $p < 0.05$  were considered significant.

394

1  
2  
3 3954  
5 396 **RESULTS & DISCUSSION**6  
7 397 **Synthesis and *in vitro* characterization of the hydrogel networks**

8 398 All polymers were successfully synthesized and fully characterized as shown in  
9  
10 399 Table 1 of the previous section. Hydrogels, analyzed for rheological behavior, showed  
11  
12 400 a continuous increase of storage modulus for both hydrogel formulations, with HA2x  
13  
14 401 hydrogels reaching higher values of  $G'$  as compared to HA1x hydrogels (**Fig. 1A**).  
15  
16 402 These data were in agreement with literature, reporting higher values of  $G'$  for  
17  
18 403 hydrogels of higher cross-link density and higher solid content (Dubbini et al., 2015;  
19  
20 404 Censi et al., 2009). Rheology measurements also demonstrated successful Michael  
21  
22 405 addition cross-linking, that progressed as  $G'$  increased. Immediately upon temperature  
23  
24 406 increase, the formulated hydrogels reached their gel-point at the temperatures of 20 and  
25  
26 407 22 °C for HA1x and HA2x hydrogels, respectively (**Fig. 1B**). Also these findings were  
27  
28 408 in agreement with literature data, demonstrating the dependence of the gel point not  
29  
30 409 only on the cloud of the polymer but also on the initial polymer content (Vermonden et  
31  
32 410 al., 2006).

33  
34 411 In order to assess the efficiency of Michael addition cross-linking, after one hour cross-  
35  
36 412 linking at 37 °C, the networks were hydrolyzed in basic conditions and the unreacted  
37  
38 413 vinyl sulfone groups were quantified according to the method previously described by  
39  
40 414 Dubbini et al., (2015). As shown in **Figure 1 C**, the chromatograms of the cross-linked  
41  
42 415 hydrogels showed no detectable peak of free DVS-3MPA, indicating that during the  
43  
44 416 chemical cross-linking reaction, the conversion of  $\alpha$ - $\beta$  unsaturated groups was, within  
45  
46 417 the experimental error, complete.

47 418

48  
49 419  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 420 When placed in contact with physiological buffer at 37 °C, both hydrogel  
4  
5 421 formulations showed hydrolytical biodegradability that led to the observation of two  
6  
7 422 different phenomena. On the one hand, the swelling and weight loss of the polymeric  
8  
9 423 matrix, and, on the other hand, the release of hyaluronic acid. **Figure 2A** shows the  
10  
11 424 swelling ratio of the two hydrogel networks as a function of time of exposition to the  
12  
13 425 physiological conditions. It can be observed how both hydrogels, already from early  
14  
15 426 time-points, demonstrated a certain tendency to absorb water, reaching SR values  
16  
17 427 between 2 and 2.5 after 5 and 10 days for HA2x and HA1x, respectively. Water uptake  
18  
19 428 is due to chain relaxation of the polymers involved in the hydrogel networks and to the  
20  
21 429 hydrolysis of the free lactate groups, that make the network more hydrophilic and prone  
22  
23 430 to water absorption. When the hydrolysis of the cross-links starts, polymer chains  
24  
25 431 solubilize in the medium resulting in weight loss by the network. The complete  
26  
27 432 dissolution of the hydrogel in medium was reached after approximately 40 and 70 days,  
28  
29 433 respectively. As expected, the hydrogels displaying a higher cross-link density and a  
30  
31 434 higher content of HA (HA2x) showed a longer residence time in physiological medium  
32  
33 435 as compared to HA1x, as a higher number of ester bonds needed to hydrolyze before  
34  
35 436 complete dissolution of the network.  
36  
37  
38  
39  
40  
41

42 437  
43 438 After a lag-phase of approximately 7 days, a continuous zero-order release of HA was  
44  
45 439 observed for both hydrogel formulations in a timeframe ranging from approximately 7  
46  
47 440 to 32 days for HA1x and from 7 to 60 days for HA2x, with tunable release rates  
48  
49 441 according to gel composition (**Fig. 2B**). Particularly, hydrogels of lower cross-link  
50  
51 442 density and lower polymer content (HA1x) displayed a faster release rate as compared  
52  
53 443 to HA2x. Zero-order kinetics are often associated to a degradation-driven release  
54  
55 444 mechanism, indicating that HA is released from the network only after hydrolysis of  
56  
57 445 the cross-links. The faster release of HA from HA1x networks depends on the faster  
58  
59  
60

1  
2  
3 446 degradation kinetics of the hydrogel (Censi et al., 2009). The degradation time of the  
4  
5 447 hydrogels corresponded with good agreement to the release time of HA. No burst  
6  
7 448 release of HA was observed, indicating that Michael addition cross-linking occurred *in*  
8  
9 449 *vitro* to a high extent and no detectable unbound HA existed. HA total recovery ranged  
10  
11 450 between 65 and 70% for both formulations. The reason for the non-quantitative  
12  
13 451 recovery of HA was the possible release of HA as aggregate to small hydrogel  
14  
15 452 fragments that may have been detached from the bulk hydrogel during the pipetting and  
16  
17 453 may have not been quantified by Azure A assay. Figure 2C shows the cumulative  
18  
19 454 release of HA expressed in absolute amount of polymer as a function of time. As  
20  
21 455 expected, HA1x released a lower amount of HA than HA2x because the initial hydrogel  
22  
23 456 formulations differed for HA content.  
24  
25  
26  
27  
28  
29  
30

### 31 458 **In vivo efficacy testing of the hydrogels in osteoarthritis mouse models**

32  
33 459 The osteoarthritic mouse model was obtained by intra-articular injection of  
34  
35 460 collagenase to anesthetized mice and the validity of the procedure was verified by X-  
36  
37 461 ray analysis one week after the treatment. Collagenase injection induced a notable  
38  
39 462 reduction of bone mineral density (BMD) (**Figure 3A**).  
40  
41

42 463 In order to evaluate whether the hyaluronic acid was able to decrease the inflammatory  
43  
44 464 process in osteoarthritic knees, the osteoarthritic mice were divided in five groups: two  
45  
46 465 groups were injected with hydrogel containing two different doses of hyaluronic acid  
47  
48 466 (4.1% and 8.2% as detailed in Materials and Methods section); the remaining three  
49  
50 467 groups, used as controls, were injected with the only saline, with the hydrogel alone or  
51  
52 468 did not received any additional injection. Our previous work evidenced that the main  
53  
54 469 decrease of pro-inflammatory cytokines, induced by hyaluronic acid, was obtained 21  
55  
56 470 days after intradermal administration in healthy mice of hydrogels composed of HA  
57  
58  
59  
60

1  
2  
3 471 and thermosensitive triblock copolymers of poly(HPMAM-lac<sub>1-2</sub>)-PEG-  
4  
5 472 poly(HPMAM-lac<sub>1-2</sub>) (Sabbieti et al., 2017). Also, according to previous observations,  
6  
7 473 the hydrogel degradation *in vivo* was accelerated by the enzymatic activity of  
8  
9 474 hyaluronidases and by cellular metabolism (Sabbiet et al., 2017), therefore it is likely  
10  
11 475 that the release of HA from the hydrogel matrices *in vivo* would be faster that that  
12  
13 476 observed *in vitro*. Hence, 21 days upon the administration of different hydrogel  
14  
15 477 formulations, all mice were anesthetized and subjected to X-ray and cardiac puncture  
16  
17 478 prior to be sacrificed.

18  
19  
20  
21 479 A statically significantly increase of BMD was observed in osteoarthritic mice  
22  
23 480 treated with HA1x or HA2x compounds, while no changes in BMD were found in  
24  
25 481 osteoarthritic mice treated with saline or HA0x, indicating that the presence and the  
26  
27 482 release of HA in the hydrogel composition was efficacious in modulating the mineral  
28  
29 483 content of bones. Moreover, the effects of hyaluronic acid effects were dose dependent,  
30  
31 484 as a more evident effect on bone remineralization was observed for HA2x with respect  
32  
33 485 to HA1x (**Fig. 3B**).

34  
35  
36  
37 486 Histological evaluation of the articular cartilage showed profound pathological changes  
38  
39 487 in mice injected with collagenase, characterized by loss of chondrocytes and  
40  
41 488 extracellular matrix proteoglycans and glycosaminoglycans (Schmitz et al., 2010)  
42  
43 489 content compared with control (**Fig. 4 A, B**). On the other hand, assessment of the knee  
44  
45 490 joints sections of mice receiving HA1x or HA2x after collagenase injections, showed a  
46  
47 491 partial restoration of the cartilage evidenced by an increase of thickness and cellularity  
48  
49 492 as well as a more homogeneous Safranin-O staining (**Figure 4 E, F**). No significant  
50  
51 493 effects in cartilage repair were found in mice treated with saline or HA0x (**Figure 4 C,**  
52  
53 494 **D**), supporting the initial hypothesis that the controlled release of HA from jellified  
54  
55 495 matrices would have a positive effect on osteoarthritis.  
56  
57  
58  
59  
60

1  
2  
3 496 Also, specific markers of mesenchymal stem cells (MSCs) differentiation in  
4  
5 497 chondroblasts such as Sox-2 and Runx-2 were evaluated in BMSCs from healthy and  
6  
7 498 osteoarthritic mice treated or untreated with hydrogels based on hyaluronic acid. In  
8  
9 499 particular, Sox-9 stimulates the production of the cartilage extracellular matrix  
10  
11 500 components such as type II collagen and aggrecan (Tsuchiya et al., 2003), while Runx-2  
12  
13 501 regulates chondroblast and osteoblast maturation (Sabbieti et al., 2009).  
14  
15

16  
17 502 As shown in **Figure 5 A**, the synthesis of both Sox-9 and Runx-2, that was  
18  
19 503 drastically down-regulated in collagenase-injected mice, was restored only by  
20  
21 504 treatments with HA2x and HA1x.  
22  
23

24 505 Previous findings demonstrated that, from a clinical point of view, osteoarthritic  
25  
26 506 patients develop synovitis to a variable extent. It is thought that several cytokines and  
27  
28 507 other mediators, particularly tumor necrosis factor (TNF)- $\alpha$  and interleukin (IL)-1, may  
29  
30 508 play a key role in both synovial inflammation and in the activation of chondrocytes and  
31  
32 509 synovial fibroblasts (Goldring and Goldring, 2007). These cytokines are able to start a  
33  
34 510 vicious cycle of stimulation of their own production, and induce the production of IL-  
35  
36 511 6, IL-8, leukocyte inhibitory factor, proteases and prostaglandins by synovial cells and  
37  
38 512 chondrocytes. It is known that TNF $\alpha$  and IL-1 are key mediators of inflammation and  
39  
40 513 articular cartilage destruction. On these bases, currently investigated therapies rely on  
41  
42 514 the use of anticytokine compounds (Bondeson et al., 2010). In line with these studies,  
43  
44 515 we found an increase of pro-inflammatory markers such as Tumor Necrosis Factor  
45  
46 516 (TNF)- $\alpha$  and nuclear factor kappa-light-chain-enhancer of activated B cells (NF $\kappa$ B) in  
47  
48 517 BMSCs from osteoarthritic mice, accompanied with an up-regulation of the  
49  
50 518 osteoclastogenic master regulator RANKL. Interestingly, the administration of HA1x  
51  
52 519 and HA2x not only diminished these inflammatory molecules but also induced a  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 520 decrease of osteoclasts maturation contrasting in this way the risks of bone loss (Fig.  
4  
5 521 **5B**).

6  
7  
8 522 Similarly, the hydrogel-hyaluronic acid compounds reduced the enhanced secretion of  
9  
10 523 pro-inflammatory cytokines/chemokines detected both in total BMCs supernatants and  
11  
12 524 in the serum of collagenase-injected mice (Fig. 6 A, B).

13  
14 525 The evidences provided in this study support the hypothesis that the controlled  
15  
16 526 release of hyaluronic acid from biocompatible and biodegradable injectable matrices  
17  
18 527 prolongs the exposure of osteoarthritic joints to hyaluronic acid. This compound  
19  
20 528 promotes the resolution of osteoarthritic-related clinical manifestations, by exerting  
21  
22 529 sustained anti-inflammatory effect. The efficacy of hyaluronic acid in osteoarthritis  
23  
24 530 may rely on its selective interactions with CD44+ cells, such as chondrocytes, that  
25  
26 531 overexpress CD44 receptors in the course of osteoarthritis (Dosio et al, 2016; Mero et  
27  
28 532 al., 2014). The primary mechanism of action of hyaluronic acid in the context of OA is  
29  
30 533 the binding with CD44 receptor (Altman et al., 2015). CD44 is a cell-surface  
31  
32 534 glycoprotein expressed in articular cells. Hyaluronic acid binding to CD44 inhibits  
33  
34 535 interleukin (IL)-1 $\beta$  expression, leading to a decline in the production of various matrix  
35  
36 536 metalloproteinase (MMP). This inhibition of MMPs prevents catabolic enzyme activity  
37  
38 537 within the joint cartilage. Furthermore, through the reduction of disintegrins and  
39  
40 538 metalloproteases, HA-CD44 binding decreases chondrocyte apoptotic events. This  
41  
42 539 decrease of chondrocyte apoptosis avoids the production of reactive oxygen species  
43  
44 540 (ROS) within the synovium, such as nitric oxide (NO), that also contributes to cartilage  
45  
46 541 degeneration. Additional events related to CD44-HA binding include reduction of  
47  
48 542 prostaglandin PGE<sub>2</sub> and increased expression of heat shock protein 70. Hyaluronic acid  
49  
50 543 regulates inflammation also via the binding with RHAMM receptors (Misra et al,  
51  
52 544 2015). It is also demonstrated that hyaluronan also regulates nerve sensitivity and  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 545 enhances the synthesis of proteoglycans (Holyoak et al., 2016). Finally, the safety,  
4  
5 546 viscoelasticity and biodegradability (enzymatic degradation by hyaluronidases) of  
6  
7 547 hyaluronan make this viscoelastic material particularly suitable as joint lubricant,  
8  
9 548 preventing cartilage degeneration through decreased friction (Maheu et al., 2016).  
10  
11 549 The continuous presentation of hyaluronic acid to the osteoarthritic joints via the  
12  
13 550 degradation-mediated release from the hydrogels, sustains over a prolonged period of  
14  
15 551 time the previously described physiological activities of the polysaccharide. This  
16  
17 552 results in a higher efficacy of treatment compared to non-cross-linked hyaluronan,  
18  
19 553 having poor residence time in the joints.  
20  
21  
22  
23  
24  
25

554

## 555 CONCLUSIONS

556 In conclusion, we showed for the first time that (HPMAM-lac<sub>1,2</sub>)-PEG-  
557 p(HPMAM-lac<sub>1,2</sub>)/thiolated hyaluronic acid hydrogels are able to contrast the  
558 inflammatory process in a mouse model of osteoarthritis through the controlled and  
559 sustained release of hyaluronic acid over a time period that goes from 30 to 70 days *in*  
560 *vitro*. In our previous research performed on healthy mice, we assumed that the  
561 observed anti-inflammatory effects of these compounds were attributable to the  
562 enrichment of the polymer networks with hyaluronic acid. In this study, we confirmed  
563 and demonstrated our hypothesis since the administration of the hydrogels not  
564 containing hyaluronic acid was did not contrast osteoarthritis, while hydrogels  
565 composed of hyaluronic acid displayed a dose-dependent effect in the reversion of  
566 inflammation related symptoms of osteoarthritis. Importantly the developed hybrid  
567 hydrogels, not only inhibited the release of inflammatory molecules, but were also able  
568 to induce mesenchymal stem cells (MSCs) maturation into chondroblasts and new  
569 cartilage formation. Since it is known that the inflammatory environments alter MSCs  
60

1  
2  
3 570 differentiation, we postulated that the reduction of inflammatory signals induced by the  
4  
5 571 sustained release of Hyaluronan, reestablished the physiological MSCs behavior.  
6  
7  
8 572 Hence, this research could provide additional insights into potential therapeutic  
9  
10 573 applications of biomaterials and, more importantly, it could suggest the use of  
11  
12 574 hyaluronic acid hydrogels as controlled delivery system for advanced therapies against  
13  
14 575 osteoarthritis.  
15  
16  
17 576

18  
19 577 **REFERENCES**

- 20  
21 578 Agas D, Gusmão Silva G, Laus F, *et al.* 2017; INF- $\gamma$  encoding plasmid administration  
22 579 triggers bone loss and disrupts bone marrow microenvironment. *J Endocrinol*  
23 580 **232**:309-21.  
24 581  
25 582 Altman RD, Manjoo A, Fierlinger A, *et al.* 2015; The mechanism of action for  
26 583 hyaluronic acid treatment in the osteoarthritic knee: a systematic review. *BMC*  
27 584 *Musculoskelet Disord* **16**: 015-0775.  
28 585  
29 586 Bellamy N, Campbell J, Robinson V, *et al.* 2006; Intraarticular corticosteroid for  
30 587 treatment of osteoarthritis of the knee. *Cochrane Database Syst Rev* **2**: CD005328.  
31 588  
32 589 Bianco P, Cao X, Frenette PS, *et al.* 2013; The meaning, the sense and the significance:  
33 590 Translating the science of mesenchymal stem cells into medicine. *Nat Med* **19**: 35-  
34 591 42.  
35 592  
36 593 Bondeson J, Blom AB, Wainwright S, *et al.* 2010; The role of synovial macrophages  
37 594 and macrophage-produced mediators in driving inflammatory and destructive  
38 595 responses in osteoarthritis. *Arthritis Rheum* **62**:647-57.  
39 596  
40 597 Censi R, Di Martino P, Vermonden T, *et al.* 2012; Hydrogels for protein delivery in  
41 598 tissue engineering. *J Control Rel* **161**: 680-92.  
42 599  
43 600 Censi R, Fieten PJ, Di Martino P, *et al.* 2010; In situ forming hydrogels by tandem  
44 601 thermal gelling and Michael addition reaction between thermosensitive triblock  
45 602 copolymers and thiolated hyaluronan. *Macromolecules* **43**:5771-78.  
46 603  
47 604 Censi R, Vermonden T, Deschout H, *et al.* 2010; Photopolymerized thermosensitive  
48 605 poly (HPMA lactate)-PEG-based hydrogels: effect of network design on mechanical  
49 606 properties, degradation, and release behavior. *Biomacromolecules* **11**: 2143-51.  
50 607  
51 608 Censi R, Vermonden T, van Steenberg MJ, *et al.* 2009; Photopolymerized  
52 609 thermosensitive hydrogels for tailorable diffusion-controlled protein delivery. *J*  
53 610 *Control Rel* **140**: 230-6.  
54 611

- 1  
2  
3 612 Chevalier X. 2010; Intraarticular treatments for osteoarthritis: new perspectives. *Curr*  
4 613 *Drug Targets* **11**: 546-60.  
5 614  
6 615 Dosio F, Arpicco S, Stella B, *et al.* 2016; Hyaluronic acid for anticancer drug and  
7 616 nucleic acid delivery. *Adv Drug Delivery Rev* **97**:204-36.  
8 617  
9 618 Dubbini A, Censi R, Butini ME, *et al.* 2015; Injectable hyaluronic acid/PEG-  
10 619 p(HPMAm-lac)-based hydrogels dually cross-linked by thermal gelling and Michael  
11 620 addition. *Europ Pol J* **72**: 423-37.  
12 621  
13 622 Glasson SS, Blanchet TJ, Morris EA. 2007; The surgical destabilization of the medial  
14 623 meniscus (DMM) model of osteoarthritis in the 129/SvEv mouse. *Osteoarthritis and*  
15 624 *Cartilage* **15**:1061-69.  
16 625  
17 626 Goldring MB, Goldring SR. 2007; Osteoarthritis. *J Cell Physiol* **213**: 626-34.  
18 627  
19 628 Goldring MB. 2000; The role of the chondrocyte in osteoarthritis. *Arthritis &*  
20 629 *Rheumatism* **43**:1916-26.  
21 630  
22 631 Hiemstra C, Zhou W, Zhong Z, *et al.* 2007; Rapidly in situ forming biodegradable  
23 632 robust hydrogels by combining stereocomplexation and photopolymerization. *J Am*  
24 633 *Chem Soc* **129**: 9918-26.  
25 634  
26 635 Holyoak DT, Tian YF, van der Meulen MC, *et al.* 2016; Osteoarthritis: Pathology,  
27 636 Mouse Models, and Nanoparticle Injectable Systems for Targeted Treatment. *Ann*  
28 637 *Biomed Eng* **44**: 2062-75.  
29 638  
30 639 Jackson DW, Simon TM. 2006; Intra-articular distribution and residence time of Hylan  
31 640 A and B: a study in the goat knee. *Osteoarthritis and Cartilage* **14**:1248-57.  
32 641  
33 642 Maheu E, Rannou F, Reginster JY. 2016; Efficacy and safety of hyaluronic acid in the  
34 643 management of osteoarthritis: Evidence from real-life setting trials and surveys.  
35 644 *Semin Arthritis Rheum* **45**: 2.  
36 645  
37 646 Marshall KW. 2000; Intra-articular hyaluronan therapy. *Curr Opin Rheumatol* **12**: 468-  
38 647 74.  
39 648  
40 649 McAlindon TE, Bannuru RR, Sullivan MC, *et al.* 2014; OARSI guidelines for the non-  
41 650 surgical management of knee osteoarthritis. *Osteoarthritis and Cartilage* **22**:363-88.  
42 651  
43 652 McManus MM, Grill RJ. 2011; Longitudinal evaluation of mouse hind limb bone loss  
44 653 after spinal cord injury using novel, in vivo, methodology. *J Vis Exp* **7**.  
45 654  
46 655 Mero A, Campisi M. 2014; Hyaluronic Acid Bioconjugates for the Delivery of  
47 656 Bioactive Molecules. *Polymers* **6**.  
48 657  
49 658 Misra S, Hascall VC, Markwald RR, *et al.* 2015; Interactions between Hyaluronan and  
50 659 Its Receptors (CD44, RHAMM) Regulate the Activities of Inflammation and  
51 660 Cancer. *Front Immunol* **6**.  
52 661

- 1  
2  
3 662 Moreland LW. 2003; Intra-articular hyaluronan (hyaluronic acid) and hylans for the  
4 663 treatment of osteoarthritis: mechanisms of action. *Arthritis Res & Ther* **5**:54-67.  
5 664  
6 665 Raynauld JP, Buckland-Wright C, Ward R, *et al.* 2003; Safety and efficacy of long-term  
7 666 intraarticular steroid injections in osteoarthritis of the knee: A randomized,  
8 667 double-blind, placebo-controlled trial. *Arthritis & Rheumatology* **48**: 370-77.  
9 668  
10 669 Riener CK, Kada G, Gruber HJ. 2002; Quick measurement of protein sulfhydryls with  
11 670 Ellman's reagent and with 4,4'-dithiodipyridine. *Anal Bioanal Chem* **373**: 266-76.  
12 671  
13 672 Sabbieti MG, Agas D, Marchetti L, *et al.* 2010; Signaling pathways implicated in  
14 673 PGF2alpha effects on Fgf2+/+ and Fgf2-/- osteoblasts. *J Cell Physiol* **224**: 465-74.  
15 674  
16 675 Sabbieti MG, Agas D, Xiao L, *et al.* 2009; Endogenous FGF-2 is critically important  
17 676 in PTH anabolic effects on bone. *J Cell Physiol* **219**: 143-51.  
18 677  
19 678 Sabbieti MG, Dubbini A, Laus F, *et al.* 2016; In vivo biocompatibility of p(HPMAm-  
20 679 lac)-PEG hydrogels hybridized with hyaluronan. *J Tissue Eng Regen Med* **11**:3056-  
21 680 3067.  
22 681  
23 682 Scanzello CR, Goldring SR. 2012; The role of synovitis in osteoarthritis pathogenesis.  
24 683 *Bone* **51**: 249-57.  
25 684  
26 685 Schmitz N, Laverty S, Kraus VB, *et al.*, 2010; Basic methods in histopathology of joint  
27 686 tissues. *Osteoarthritis and Cartilage* **18**: S113eS116.  
28 687  
29 688 Sellam J, Berenbaum F. 2010; The role of synovitis in pathophysiology and clinical  
30 689 symptoms of osteoarthritis. *Nat Rev Rheumatol* **6**:625-35.  
31 690  
32 691 Shu XZ, Liu Y, Luo Y, *et al.* 2002; Disulfide cross-linked hyaluronan hydrogels.  
33 692 *Biomacromolecules* **3**:1304-11.  
34 693  
35 694 Soga O, van Nostrum CF, Hennink WE. 2004; Poly(N-(2-hydroxypropyl)  
36 695 methacrylamide mono/di lactate): a new class of biodegradable polymers with  
37 696 tuneable thermosensitivity. *Biomacromolecules* **5**:818-21.  
38 697  
39 698 Sophia Fox AJ, Bedi A, Rodeo SA. 2009; The Basic Science of Articular Cartilage:  
40 699 Structure, Composition, and Function. *Sports Health* **1**:461-68.  
41 700  
42 701 Tsuchiya H, Kitoh H, Sugiura F, *et al.* 2003; Chondrogenesis enhanced by  
43 702 overexpression of sox9 gene in mouse bone marrow-derived mesenchymal stem  
44 703 cells. *Biochem Biophys Res Commun* **301**: 338-43.  
45 704  
46 705 van der Kraan PM, Vitters EL, van Beuningen HM, *et al.* 1990: Degenerative knee joint  
47 706 lesions in mice after a single intra-articular collagenase injection. A new model of  
48 707 osteoarthritis. *J Exp Pathol* **71**:19-31.  
49 708  
50 709 Vercruyssen KP, Marecak DM, Marecek JF, *et al.* 1997; Synthesis and in vitro  
51 710 degradation of new polyvalent hydrazide cross-linked hydrogels of hyaluronic acid.  
52 711 *Bioconjug Chem* **8**: 686-94.

- 1  
2  
3 712  
4 713 Vermonden T, Besseling NAM, van Steenberg MJ, *et al.* 2006; Rheological Studies  
5 714 of Thermosensitive Triblock Copolymer Hydrogels. *Langmuir* **22**:10180-84.  
6 715  
7 716 Waung JA, Maynard SA, Gopal S, *et al.* 2014; Quantitative X-ray microradiography  
8 717 for high-throughput phenotyping of osteoarthritis in mice. *Osteoarthritis and*  
9 718 *Cartilage* **22**:1396-400.  
10 719  
11 720 Zhang Y, Jordan JM. 2010; Epidemiology of Osteoarthritis. *Clinics in geriatric*  
12 721 *medicine* **26**: 355-69.  
13 722  
14 723  
15 724  
16 725  
17 726  
18 727  
19 728  
20 729  
21 730  
22 731  
23 732  
24 733  
25 734  
26 735  
27 736  
28 737  
29 738  
30 739  
31 740  
32 741  
33 742  
34 743  
35 744  
36 745  
37 746  
38 747  
39 748  
40 749  
41 750  
42 751

## FIGURE LEGENDS

**Figure 1.** Rheology measurements of HA1x and HA2x hydrogels. Storage moduli ( $G'$ ) and loss moduli ( $G''$ ) as a function of time at increasing temperature (A). Close-up image of rheology experiments, where the gel point is observed at the cross-point of  $G'$  and  $G''$  (B). HPLC analysis of unreacted vinyl sulfone groups of HA2x hydrogels after 1 hour Michael addition cross-linking at 37°C. Comparison with standard vinyl sulfone and vinyl sulfone hydrolyzed from uncross-linked hydrogels (C).

**Figure 2.** Swelling and degradation profiles of HA1x and HA2x hydrogels shown as the variation in time of the SR value during storage of the networks in physiological conditions (exposure to phosphate buffer at pH 7,4 and 37 °C (A). HA release profiles from HA1x and HA2x hydrogels: cumulative release profile % as a function of time (B); cumulative release profile in mg as a function of time (C).

**Figure 3.** Pseudo-color images of X-ray images obtained converting the original 16 bit DICOM X-ray radiographs to an 8 bit TIFF format and pseudo-coloring the resultant image using a 16 color look-up table. In pseudo-color images, lower bone mineral density (BMD) is represented in green and yellow pseudo-colors, while higher BMD is represented in red and purple pseudo-colors. Histograms represent the BMD calculated in the areas selected (ROI). The decreased BMD after intraarticular injection of collagenase is visualized in green/yellow pseudo-color. The treatment

1  
2  
3 752 with HA1A HA2x hydrogel in collagenase-injected mice restore the BMD,  
4 753 (yellow/purple and red/white pseudo-color, respectively) in dose dependent manner  
5 754 (A, B).  
6  
7  
8  
9

10 756 **Figure 4.** Representative Safranin-O/fast green stained histological sections of the knee  
11 757 joints in all mice groups (n = 6 mice/group) (A-F). Arrows indicated areas of  
12 758 hypocellularity after collagenase injection (B). HA1x and HA2x compounds  
13 759 reconstitute the cartilage thickness and cellularity (E, F). Magnification 10x.  
14 760 Cartilage erosion scores for femoral and tibial surfaces. Scores (mean±SE) shown  
15 761 with femoral condyles and tibial plateaus. Each group consisted of 6 animals (G).  
16  
17  
18  
19  
20  
21

22 763 **Figure 5.** Representative western blotting of SOX-9 and RUNX2 expression levels in  
23 764 BMSCs obtained from all the mice groups (A). Representative western blotting of  
24 765 TNF- $\alpha$ , NF $\kappa$ B, and RANKL levels in BMSCs from all the mice groups (B). Data  
25 766 were analyzed by using two-way ANOVA. Lowercase letters denote homogeneous  
26 767 subsets. Error bars represent  $\pm$  SE ( $p < 0.05$ )  
27  
28  
29  
30  
31

32 769 **Figure 6.** Cytokines release analyzed in medium from total bone marrow cell (BMCs)  
33 770 cultures (A) and in serum (B) of the all mice groups; Data were analyzed by using  
34 771 two-way ANOVA. Lowercase letters denote homogeneous subsets. Error bars  
35 772 represent  $\pm$  SE ( $p < 0.05$ )  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Figure 1




Figure 1. Rheology measurements of HA1x and HA2x hydrogels. Storage moduli ( $G'$ ) and loss moduli ( $G''$ ) as a function of time at increasing temperature (A). Close-up image of rheology experiments, where the gel point is observed at the cross-point of  $G'$  and  $G''$  (B). HPLC analysis of unreacted vinyl sulfone groups of HA2x hydrogels after 1 hour Michael addition cross-linking at  $37^{\circ}\text{C}$ . Comparison with standard vinyl sulfone and vinyl sulfone hydrolyzed from uncross-linked hydrogels (C).




Figure 2. Swelling and degradation profiles of HA1x and HA2x hydrogels shown as the variation in time of the SR value during storage of the networks in physiological conditions (exposure to phosphate buffer at pH 7,4 and 37 °C (A)). HA release profiles from HA1x and HA2x hydrogels: cumulative release profile % as a function of time (B); cumulative release profile in mg as a function of time (C).



Figure 3




Figure 3. Pseudo-color images of X-ray images obtained converting the original 16 bit DICOM X-ray radiographs to an 8 bit TIFF format and pseudo-coloring the resultant image using a 16 color look-up table. In pseudo-color images, lower bone mineral density (BMD) is represented in green and yellow pseudo-colors, while higher BMD is represented in red and purple pseudo-colors. Histograms represent the BMD calculated in the areas selected (ROI). The decreased BMD after intraarticular injection of collagenase is visualized in green/yellow pseudo-color. The treatment with HA1A HA2x hydrogel in collagenase-injected mice restore the BMD, (yellow/purple and red/white pseudo-color, respectively) in dose dependent manner (A, B).




Figure 4. Representative Safranin-O/fast green stained histological sections of the knee joints in all mice groups (n = 6 mice/group) (A-F). Arrows indicated areas of hypocellularity after collagenase injection (B). HA1x and HA2x compounds reconstitute the cartilage thickness and cellularity (E, F). Magnification 10x. Cartilage erosion scores for femoral and tibial surfaces. Scores (mean±SE) shown with femoral condyles and tibial plateaus. Each group consisted of 6 animals (G).

Figure 5




Figure 5. Representative western blotting of SOX-9 and RUNX2 expression levels in BMSCs obtained from all the mice groups (A). Representative western blotting of TNF- $\alpha$ , NFkB, and RANKL levels in BMSCs from all the mice groups (B). Data were analyzed by using two-way ANOVA. Lowercase letters denote homogeneous subsets. Error bars represent  $\pm$  SE ( $p < 0.05$ )




Figure 6. Cytokines release analyzed in medium from total bone marrow cell (BMCs) cultures (A) and in serum (B) of the all mice groups; Data were analyzed by using two-way ANOVA. Lowercase letters denote homogeneous subsets. Error bars represent  $\pm$  SE ( $p < 0.05$ )

**Table 1.** Overview of the main characteristics of the polymers used in the formulation of the hydrogels studied in the present work.

	Mn*	Mn**	Mw**	PDI**	Cloud point <sup>□</sup> (°C)	DS*	Yield
	(kDa)	(kDa)	(kDa)			(%)	(%)
VinylSulTC_0	47	25.7	52.5	2.04	24	0	70
VinylSulTC_10	54	25.8	54.2	2.1	22	8	100
VinylSulTC_15	55	26.1	57.2	2.06	19	16	97
HA-SH_56	38	-	37.9 <sup>†</sup>	-	-	18	82

\*Based on <sup>1</sup>H-NMR

\*\*Based on GPC

□ Based on Light Scattering

† According to producer specifications

**Table 2.** Table summarizing mice groups use and treatments

<b>GROUP</b>	<b>Intraarticular injection</b>	<b>Intradermal Injection</b>	
<b>G1</b> (6 mice) control	Saline 10 $\mu$ l	No further treatment	
<b>G2</b> (30 mice)	Collagenase 10 $\mu$ l (1 mg/ml)	<b>G2a</b> (6 mice)	No further treatment
		<b>G2b</b> (6 mice)	50 $\mu$ l saline
		<b>G2c</b> (6 mice)	50 $\mu$ l hydrogel 15% w/w VinylSulfTC_0 ( <b>HA0x</b> )
		<b>G2d</b> (6 mice)	50 $\mu$ l hydrogel 15% w/w VinylSulfTC_10 4.1% w/w HA-SH_56 ( <b>HA1x</b> )
		<b>G2e</b> (6 mice)	10 $\mu$ l hydrogel 15% w/w VinylSulfTC_15 8.2% w/w HA-SH_56 ( <b>HA2x</b> )